Synthetic Biologics, Inc. SYN Income Statement

Synthetic biologics, inc. (SYN)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Operating Costs and Expenses:
License revenue, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	2,125
Laboratory revenues, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	289	69
Total Revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	289	2,194
General and administrative
1,393	1,284	1,098	1,044	1,154	1,202	1,474	1,431	1,620	2,028	1,705	1,644	2,090	3,475	2,095	2,147	2,426	2,535	1,604	2,222	1,713	1,859	1,218	1,814	1,122	1,562	1,890	1,258	1,122	1,295	1,073	1,176	1,468	249	582	524	1,233	601	662
Research and development
1,635	1,927	4,144	2,594	2,418	2,056	2,846	3,572	3,370	3,757	4,137	4,831	6,059	6,729	7,061	7,164	8,155	8,858	10,046	7,508	6,494	5,242	3,693	2,837	2,717	2,711	1,475	1,203	1,118	10,591	763	547	386	2,539	289	281	231	229	426
Costs of laboratory services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	192	132
Total Operating Costs and Expenses
3,028	3,211	5,242	3,638	3,572	3,258	4,320	5,003	4,990	5,785	5,842	6,475	8,149	10,204	9,156	9,311	10,581	11,393	11,650	9,730	8,207	7,101	4,911	4,651	3,839	4,273	3,365	2,461	2,240	11,886	1,836	1,723	1,854	2,788	871	805	1,464	1,023	1,221
Loss from Operations
-3,028	-3,211	-5,242	-3,638	-3,572	-3,258	-4,320	-5,003	-4,990	-5,785	-5,842	-6,475	-8,149	-10,204	-9,156	-9,311	-10,581	-11,393	-11,650	-9,730	-8,207	-7,101	-4,911	-4,651	-3,839	-	-3,365	-	-	-	-	-	-	-	-	-	-	-733	973
Loss from Operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,461	-2,240	-	-1,836	-1,723	-1,854	-2,788	-871	-805	-1,464	-	-
Other Income :
Change in fair value of warrant liability
-	-	0	0	-	-19	-626	-783	-2,655	-8,581	5,092	-2,159	-5,090	-7,731	-666	-3,513	498	-95	-4,141	3,895	4,152	-620	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	95	-	47	-14	-46	1	-40	10	7	5	-	-	-	-	-	-
Warrant expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	776	716	-	-
Change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1	165	-16	94	-	-
Warrant expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Interest income
38	67	92	80	44	47	5	6	9	15	4	1	1	1	1	34	1	1	2	2	1	1	1	0	1	1	11	10	11	33	0	0	0	-	-	-	-	0	-
Loss on the sale of equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5	-	-
Other income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	-1	56	0	6
Total Other Income
38	67	92	80	44	66	631	789	2,664	8,596	-5,088	2,160	5,091	7,732	667	3,547	-497	96	4,143	-3,893	-4,151	621	1	95	1	48	-3	-36	12	-7	10	7	5	-19	-159	-761	-759	0	6
Loss from Continuing Operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11,893	-1,826	-1,716	-1,849	-2,807	-1,030	-1,566	-2,223	-	-
Income from Discontinued Operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-173	-104	-156	649	-378	-68	-114	37	-	-
Net Loss
-2,990	-3,144	-5,150	-3,558	-3,528	-3,192	-3,689	-4,214	-2,326	2,811	-10,930	-4,315	-3,058	-2,472	-8,489	-5,764	-11,078	-11,297	-7,507	-13,623	-12,358	-6,480	-4,910	-4,556	-3,838	-4,225	-3,368	-2,497	-2,228	-	-	-	-	-	-	-	-	-	-
Net Loss Attributable to Non-controlling Interest
-26	-4	-30	-27	-16	-18	-9	-17	-10	-38	-8	-60	-212	-97	-136	-82	-233	-315	-733	0	0	0	0	0	0	-1	0	0	0	-	-	-	-	-	-	-	-	-	-
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries
-2,964	-3,140	-5,120	-3,531	-3,512	-3,174	-3,680	-4,197	-2,316	2,849	-10,922	-4,255	-2,846	-2,375	-8,353	-5,682	-10,845	-10,982	-6,774	-13,623	-12,358	-6,480	-4,910	-4,556	-3,838	-4,224	-3,368	-2,497	-2,228	-12,066	-1,930	-1,872	-1,200	-3,185	-1,098	-1,680	-2,186	-732	979
Preferred Stock Dividends, Income Statement Impact
-	-	-	-	-	-	-	-	-	-6,828	6,901	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Loss Attributable to Common Stockholders
-3,430	-3,143	-5,253	-3,709	-3,971	-14,917	-3,741	-4,258	-2,375	2,788	-17,823	-4,255	-2,846	-	-8,353	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Loss Per Share - Basic and Dilutive (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.08	-0.07	-	-0.08	-0.06	-0.05	-0.34	-0.05	-0.05	-0.06	-0.08	-0.04	-0.06	-0.09	-	-
Discontinued operations (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.01	0.00	0.00	0.02	-0.02	0.00	0.00	0.00	-	-
Net Loss Per Share - Basic and Dilutive
-0.20	-0.19	-0.31	-0.23	-0.25	-1.32	-0.93	-1.16	-0.65	-1.28	-4.90	-0.03	-0.02	-0.02	-0.09	-0.06	-0.12	-	-	-	-0.17	-	-	-0.08	-0.07	-0.08	-0.08	-0.06	-0.05	-0.35	-0.05	-0.05	-0.04	-0.10	-0.04	-0.06	-0.09	-0.03	-
Weighted average number of shares outstanding during the period - Basic and Dilutive
17,093	16,825	16,805	16,465	15,656	13,544	4,028	3,683	3,673	-229,904	3,665	123,005	117,447	-	91,441	-	90,826	-	-	-	72,673	-	-	58,453	58,324	48,761	44,654	44,654	44,601	41,188	33,383	33,011	32,003	-	28,089	27,885	-	-	-
Net Loss Per Share - Basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.08	-0.19	-	-	-0.08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.05
Net Loss Per Share - Dilutive
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.10	-	-	-0.12	-0.19	-	-	-0.08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.05
Weighted average number of shares outstanding during the period - Basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	91,015	-	-	85,974	72,736	-	-	58,453	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,706
Weighted average number of shares outstanding during the period - Dilutive
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	93,930	-	-	87,585	72,736	-	-	58,453	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,883
Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25,220	23,003	-
Series B Preferred Stock [Member]
Net Loss Attributable to Non-controlling Interest
0	-	0	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries
0	-	0	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred Stock Dividends, Income Statement Impact
404	-60	70	117	398	11,681	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Series A Preferred Stock [Member]
Preferred Stock Dividends, Income Statement Impact
62	15	63	61	61	19	61	61	59	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-